ArticleCureus2025
Surgical Outcomes of 108 Patients Undergoing Holmium Laser Enucleation of the Prostate Over Three Years in a Rural District General Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAn emerging method to treat benign prostatic hyperplasia (BPH) is Holmium Laser Enucleation of the Prostate (HoLEP). This study aims to evaluate the feasibility, safety, and functional outcomes of introducing a HoLEP service in a rural UK District General Hospital (DGH).
methodsThis was a retrospective study of 108 consecutive patients who underwent HoLEP between April 2022 and April 2025, performed by a single surgeon at a rural district general hospital. Perioperative parameters, histology, functional outcomes (International Prostate Symptom Score (I-PSS), quality of life (QoL), maximum urinary flow rate (Qmax), residual volume (RV), and prostate-specific antigen (PSA)), and complications (Clavien-Dindo classification) were analyzed. Nonparametric tests were used to compare preoperative and postoperative data; results are reported with mean differences and P values.
resultsMean prostate volume was 104 mL, with a mean resected weight of 54 g and a mean operative time of 139 minutes. Significant postoperative improvements were observed across all functional domains: Qmax (+11 mL/s), RV (-196 mL), I-PSS (-12.6 points), QoL (-2.3 points), and PSA (-5.9 ng/mL), all p<0.001. Histology confirmed BPH in 88% and incidental prostate cancer in 7%. Limitations include incomplete follow-up and the absence of a comparator group.
conclusionHoLEP can be delivered safely and effectively in a rural DGH, with substantial functional improvements and low rates of clinically significant complications. Broader dissemination of HoLEP beyond tertiary centers is feasible, but comparative and cost-effectiveness studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.